XAIR Stock Forecast 2025-2026
Distance to XAIR Price Targets
XAIR Price Momentum
10 Quality Stocks Worth Considering Now
Researching Beyond Air (XAIR) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on XAIR and similar high-potential opportunities.
Latest XAIR Stock Price Targets & Analyst Predictions
Based on our analysis of 7 Wall Street analysts, XAIR has a bullish consensus with a median price target of $1.50 (ranging from $1.00 to $5.00). The overall analyst rating is Strong Buy (8.0/10). Currently trading at $0.27, the median forecast implies a 457.6% upside. This outlook is supported by 4 Buy, 1 Hold, and 0 Sell ratings.
Conversely, the most conservative target is provided by Jason Bednar at Piper Sandler, suggesting a 271.7% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
XAIR Analyst Ratings
XAIR Price Target Range
Latest XAIR Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for XAIR.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Aug 16, 2024 | Roth MKM | Jason White | Buy | Reinstates | $2.00 |
| Aug 7, 2024 | Piper Sandler | Jason Bednar | Overweight | Maintains | $1.00 |
| Jun 25, 2024 | BTIG | Marie Thibault | Neutral | Downgrade | $0.00 |
| Jun 25, 2024 | Piper Sandler | Jason Bednar | Overweight | Maintains | $3.50 |
| Apr 30, 2024 | Truist Securities | Gregory Fraser | Buy | Maintains | $8.00 |
| Nov 14, 2023 | Truist Securities | Gregory Fraser | Buy | Maintains | $10.00 |
| Jul 28, 2023 | Piper Sandler | Jason Bednar | Overweight | Initiates | $10.00 |
| Jul 21, 2023 | Truist Securities | Gregory Fraser | Buy | Maintains | $14.00 |
| Jun 23, 2023 | Oppenheimer | Suraj Kalia | Outperform | Maintains | $10.00 |
| Jun 15, 2023 | BTIG | Buy | Initiates | $0.00 | |
| Jun 29, 2022 | Truist Securities | Gregory Fraser | Buy | Maintains | $20.00 |
| Jun 29, 2022 | Ladenburg Thalmann | Matthew Kaplan | Buy | Maintains | $23.00 |
| Nov 12, 2021 | Truist Securities | Gregory Fraser | Buy | Maintains | $16.00 |
| Apr 28, 2021 | Truist Securities | Buy | Initiates | $0.00 | |
| Oct 22, 2019 | Oppenheimer | Outperform | Initiates | $0.00 |
Beyond Air Inc. (XAIR) Competitors
The following stocks are similar to Beyond Air based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Beyond Air Inc. (XAIR) Financial Data
Beyond Air Inc. has a market capitalization of $23.71M with a P/E ratio of -0.1x. The company generates $3.02M in trailing twelve-month revenue with a -112.8% profit margin.
Revenue growth is +174.2% quarter-over-quarter, while maintaining an operating margin of -1,021.6% and return on equity of -262.7%.
Valuation Metrics
Growth & Margins
Financial Health
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Beyond Air Inc. (XAIR) Business Model
About Beyond Air Inc.
Develops innovative therapies for respiratory conditions.
The company generates revenue by developing and commercializing medical devices and therapies that utilize nitric oxide for treating respiratory ailments. By pioneering new delivery systems, Beyond Air Inc. aims to transform respiratory care and expand its market presence in the healthcare sector.
Beyond Air Inc. is headquartered in Garden City, New York, and focuses on addressing significant respiratory diseases, including COPD and bronchiolitis. The company is positioned at the intersection of biotechnology and medical technology, potentially influencing various sectors such as pharmaceuticals and medical device manufacturing.
Company Information
Sector
Healthcare
Industry
Medical Devices
Employees
107
CEO
Mr. Steven Adam Lisi
Country
United States
IPO Year
2018
Website
www.beyondair.netBeyond Air Inc. (XAIR) Latest News & Analysis
Beyond Air, Inc. has expanded its international distribution network for LungFit PH to 18 countries, securing new agreements in France, Turkey, Romania, and Morocco, and has received initial orders.
Beyond Air's expansion into four new countries enhances its market reach for LungFit PH, potentially increasing sales and revenues, which could positively impact stock performance.
Beyond Air, Inc. (NASDAQ: XAIR) will participate in the Roth 37th Annual Growth Stock Conference on March 16-18, 2025, and the Jones Healthcare Conference on April 8-9, 2025.
Steve Lisi's participation in key conferences may enhance Beyond Air's visibility, attract potential investors, and signal confidence in the company's growth prospects in the medical sector.
Beyond Air, Inc. (NASDAQ: XAIR) will host its Q3 2025 results conference call on February 10, 2025, at 4:30 PM ET, featuring key executives and financial analysts.
The upcoming conference call will provide insights into Beyond Air's Q3 2025 financial performance, crucial for assessing its growth and investment potential.
Beyond Air® Reports Fiscal Third Quarter 2025 Financial Results and Provides Corporate Update
1 month agoBeyond Air, Inc. (NASDAQ: XAIR) reported a 34% revenue increase from the prior quarter, surpassing $1 million. The company received CE Mark approval in Europe and market authorization in Australia for LungFit PH.
Beyond Air's 34% revenue growth and CE Mark approval for LungFit PH indicate strong market potential and expansion, likely boosting investor confidence and stock performance.
Beyond Air, Inc. (XAIR) reported a quarterly loss of $0.15 per share, better than the expected loss of $0.18, and an improvement from a loss of $0.50 per share a year prior.
Beyond Air's smaller quarterly loss than expected signals improved financial performance, potentially boosting investor confidence and interest in the stock.
Beyond Air® Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Requirement
1 month agoBeyond Air, Inc. (NASDAQ: XAIR) has been granted an additional 180 days, until August 4, 2025, to comply with Nasdaq's minimum bid price rule, allowing its stock to continue trading.
Beyond Air's extension to regain compliance with Nasdaq's bid price rule allows continued trading, signaling potential recovery opportunities for investors while mitigating immediate delisting risks.
Frequently Asked Questions About XAIR Stock
What is Beyond Air Inc.'s (XAIR) stock forecast for 2025?
Based on our analysis of 7 Wall Street analysts, Beyond Air Inc. (XAIR) has a median price target of $1.50. The highest price target is $5.00 and the lowest is $1.00.
Is XAIR stock a good investment in 2025?
According to current analyst ratings, XAIR has 4 Buy ratings, 1 Hold ratings, and 0 Sell ratings. The stock is currently trading at $0.27. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for XAIR stock?
Wall Street analysts predict XAIR stock could reach $1.50 in the next 12 months. This represents a 457.6% increase from the current price of $0.27. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Beyond Air Inc.'s business model?
The company generates revenue by developing and commercializing medical devices and therapies that utilize nitric oxide for treating respiratory ailments. By pioneering new delivery systems, Beyond Air Inc. aims to transform respiratory care and expand its market presence in the healthcare sector.
What is the highest forecasted price for XAIR Beyond Air Inc.?
The highest price target for XAIR is $5.00 from at , which represents a 1,758.7% increase from the current price of $0.27.
What is the lowest forecasted price for XAIR Beyond Air Inc.?
The lowest price target for XAIR is $1.00 from Jason Bednar at Piper Sandler, which represents a 271.7% increase from the current price of $0.27.
What is the overall XAIR consensus from analysts for Beyond Air Inc.?
The overall analyst consensus for XAIR is bullish. Out of 7 Wall Street analysts, 4 rate it as Buy, 1 as Hold, and 0 as Sell, with a median price target of $1.50.
How accurate are XAIR stock price projections?
Stock price projections, including those for Beyond Air Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
